Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

421. Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review

Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

422. Outcomes of children and adolescents with well-differentiated thyroid carcinoma and pulmonary metastases following 131I treatment: a systematic review

Outcomes of children and adolescents with well-differentiated thyroid carcinoma and pulmonary metastases following 131I treatment: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

423. EANM procedure guidelines for therapy of benign thyroid disease

EANM procedure guidelines for therapy of benign thyroid disease GUIDELINES EANM procedure guidelines for therapy of benign thyroid disease Marcel P. M. Stokkel &Daria Handkiewicz Junak & Michael Lassmann &Markus Dietlein &Markus Luster Received: 16 June 2010/Accepted: 17 June 2010/Published online: 13 July 2010 # Springer-Verlag 2010 Abstract The purpose of the present guidelines on the 131 I therapy of benign thyroid disorders formulated by the European Association of Nuclear Medicine (EANM (...) ) Therapy Committee is to provide advice to nuclear medicine clinicians on how to treat benign thyroid conditions employing optimal 131 I activities. The recom- mendations were formulated based on recent literature and expert opinion regarding rationale, indications and contraindications for the use of 131 I procedures, as well as the adequate 131 I activities in different thyroid disorders, and the administration and patient preparation techniques to be used. Recommendations are also provided

2010 European Association of Nuclear Medicine

424. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective Full Text available with Trip Pro

Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective Mernagh P, Suebwongpat A, Silverberg J, Weston A Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of recombinant human thyroid-stimulating hormone (rhTSH) before radioiodine ablation in patients with low-risk thyroid cancer. The authors concluded

2010 NHS Economic Evaluation Database.

425. Use of color Doppler ultrasonography for the prediction of malignancy in follicular thyroid neoplasms: systematic review and meta-analysis

Use of color Doppler ultrasonography for the prediction of malignancy in follicular thyroid neoplasms: systematic review and meta-analysis Use of color Doppler ultrasonography for the prediction of malignancy in follicular thyroid neoplasms: systematic review and meta-analysis Use of color Doppler ultrasonography for the prediction of malignancy in follicular thyroid neoplasms: systematic review and meta-analysis Iared W, Shigueoka DC, Cristofoli JC, Andriolo R, Atallah AN, Ajzen SA, Valente O (...) CRD summary This review concluded that predominant internal flow seen on colour Doppler ultrasound was associated with malignancy of thyroid follicular neoplasms; absence of internal flow or predominantly peripheral flow indicated low probability of malignancy. The small number and relatively poor quality of included studies and lack of reporting of analytical methods mean that these conclusions should be interpreted cautiously. Authors' objectives To assess the diagnostic accuracy of colour

2010 DARE.

426. Thyroid cancer and renal transplantation: a meta-analysis

Thyroid cancer and renal transplantation: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

427. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States Full Text available with Trip Pro

To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States To stimulate or withdraw? A cost-utility analysis of recombinant human (...) thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States Wang TS, Cheung K, Mehta P, Roman SA, Walker HD, Sosa JA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD

2010 NHS Economic Evaluation Database.

428. Cross sectional study: Risk of other autoimmune diseases increased in people with Graves' disease or Hashimoto's thyroiditis relative to the general UK population

Cross sectional study: Risk of other autoimmune diseases increased in people with Graves' disease or Hashimoto's thyroiditis relative to the general UK population Risk of other autoimmune diseases increased in people with Graves' disease or Hashimoto's thyroiditis relative to the general UK population | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn (...) or Hashimoto's thyroiditis relative to the general UK population Article Text Causation Cross sectional study Risk of other autoimmune diseases increased in people with Graves' disease or Hashimoto's thyroiditis relative to the general UK population Philip E Knapp Statistics from Altmetric.com Commentary on: Boelaert K , Newby PR , Simmonds MJ , et al . Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease . Autoimmune thyroid disease, including Grave's disease

2010 Evidence-Based Medicine

429. The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis Full Text available with Trip Pro

The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin (...) and negative scan: a meta-analysis Ma C, Xie J, Lou Y, Gao Y, Zuo S, Wang X CRD summary This review concluded that thyroid stimulating hormone stimulation should be recommended for differentiated thyroid carcinoma patients who underwent positron emission tomography scanning for detection of thyroglobulin-positive and radioiodine-negative metastases. Given the limitations of the data available, this conclusion seems overly strong. The authors' recommendation for further research seems justified. Authors

2010 DARE.

430. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. Full Text available with Trip Pro

Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. Dyslipidemia increases the risk of atherosclerotic cardiovascular disease and is incompletely reversed by statin therapy alone in many patients. Thyroid hormone lowers levels of serum low-density lipoprotein (LDL) cholesterol and has other potentially favorable actions on lipoprotein metabolism. Consequently, thyromimetic drugs hold promise as lipid-lowering agents if adverse effects can be avoided.We performed (...) of serum apolipoprotein B, triglycerides, and Lp(a) lipoprotein. Eprotirome therapy was not associated with adverse effects on the heart or bone. No change in levels of serum thyrotropin or triiodothyronine was detected, although the thyroxine level decreased in patients receiving eprotirome.In this 12-week trial, the thyroid hormone analogue eprotirome was associated with decreases in levels of atherogenic lipoproteins in patients receiving treatment with statins. (ClinicalTrials.gov number

2010 NEJM Controlled trial quality: predicted high

431. DITPA (3,5-Diiodothyropropionic Acid), a Thyroid Hormone Analog to Treat Heart Failure: Phase II Trial Veterans Affairs Cooperative Study Full Text available with Trip Pro

DITPA (3,5-Diiodothyropropionic Acid), a Thyroid Hormone Analog to Treat Heart Failure: Phase II Trial Veterans Affairs Cooperative Study In animal studies and a pilot trial in patients with congestive heart failure, the thyroid hormone analog 3,5 diiodothyropropionic acid (DITPA) had beneficial hemodynamic effects.This was a phase II multicenter, randomized, placebo-controlled, double-blind trial of New York Heart Association class II to IV congestive heart failure patients randomized (2:1 (...) frequent in the DITPA group. DITPA increased cardiac index (by 18%) and decreased systemic vascular resistance (by 11%), serum cholesterol (-20%), low-density lipoprotein cholesterol (-30%), and body weight (-11 lb). Thyroid-stimulating hormone was suppressed in patients given DITPA, which reflects its thyromimetic effect; however, no symptoms or signs of potential hypothyroidism or thyrotoxicosis were seen.DITPA improved some hemodynamic and metabolic parameters, but there was no evidence

2009 EvidenceUpdates Controlled trial quality: predicted high

432. Thyroid peroxidase antibodies in pregnant women with type 1 diabetes: impact on thyroid function, metabolic control and pregnancy outcome (Abstract)

Thyroid peroxidase antibodies in pregnant women with type 1 diabetes: impact on thyroid function, metabolic control and pregnancy outcome In pregnant women with type 1 diabetes, we evaluated whether the presence of thyroid peroxidase autoantibodies (anti-TPO) was associated with changes in thyroid function, metabolic control and pregnancy outcome.Prospective study, Denmark.Ninety-six consecutive pregnant women with type 1 diabetes. Twenty-five healthy pregnant controls.At 8, 14, 21, 27 and 33 (...) -TPO negative women. Twenty untreated anti-TPO positive women had higher TSH compared with untreated, anti-TPO negative women (p<0.05), but comparable free T4. At inclusion, 25% had TSH above the recommended treatment goal for levothyroxine (TSH>2.5 mIU/l), most prevalently among anti-TPO positive women. Sixteen women (17%) were treated for thyroid disorder during pregnancy. No differences were detected between the diabetic women with and without anti-TPO regarding HbA1C, insulin dose, median SMPG

2009 EvidenceUpdates

433. High versus low dose of initial thyroid hormone replacement for congenital hypothyroidism. (Abstract)

High versus low dose of initial thyroid hormone replacement for congenital hypothyroidism. Congenital hypothyroidism (CHT) affects approximately one in 3000 to 4000 infants. CHT is one of the most common preventable causes of learning difficulties. Optimal management of CHT requires early diagnosis and prompt treatment to avoid abnormal neurodevelopmental outcome. One of the main issues in the management of CHT relates to the initial dose of levothyroxine to be used in order to achieve optimal (...) results in terms of intellectual development. Currently, it remains unclear whether high dose thyroid hormone replacement is more effective than low dose in the treatment of CHT. Further research is required to determine an appropriate dose that improves mental and psychomotor developmental outcomes.To determine the effects of high versus low dose of initial thyroid hormone replacement for congenital hypothyroidism.Randomised controlled trials were identified by searching The Cochrane Library, MEDLINE

2009 Cochrane

434. Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. (Abstract)

Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. Differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases has been observed in follow-up studies. The management of this condition remains controversial. Most studies support blind radioactive iodine treatment while others negate this approach.To assess the effects of radioiodine therapy for differentiated thyroid (...) author entered data into a data extraction form and the second one verified the results of this procedure.Because of the absence of any suitable randomised or prospective controlled trial in this area, results currently cannot be presented.The currently available evidence is insufficient to reliably assess the potential of radioiodine treatment for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.

2009 Cochrane

435. ACR-SNMMI-SPR Practice Guideline for the Performance of Thyroid Scintigraphy and Uptake Measurements

ACR-SNMMI-SPR Practice Guideline for the Performance of Thyroid Scintigraphy and Uptake Measurements The American College of Radiology, with more than 30,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study the socioeconomic aspects of the practice (...) ) A. Radiopharmaceuticals 1. Radiopharmaceuticals taken up by the thyroid in proportion to thyroid function (see the ACR– SNM–SPR Practice Guideline for the Performance of Thyroid Scintigraphy and Uptake Measurements). a. Technetium-99m pertechnetate, given intravenously in an administered activity of 1 to 10 millicuries (37 to 370 MBq), depending on the protocol used, is trapped by the follicular cells of the thyroid. b. Iodine-123 (sodium iodide), given orally in an administered activity of 200 to 600 microcuries

2009 Society of Nuclear Medicine and Molecular Imaging

436. Revised American Thyroid Association Guidelines for DTC and Thyroid Nodule

Revised American Thyroid Association Guidelines for DTC and Thyroid Nodule ORIGINAL STUDIES, REVIEWS, AND SCHOLARLY DIALOG THYROID CANCER AND NODULES Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer David S. Cooper, M.D. 1 (Chair) * , Gerard M. Doherty, M.D., 2 Bryan R. Haugen, M.D., 3 Richard T. Kloos, M.D (...) ., 4 Stephanie L. Lee, M.D., Ph.D., 5 Susan J. Mandel, M.D., M.P.H., 6 Ernest L. Mazzaferri, M.D., 7 Bryan McIver, M.D., Ph.D., 8 Furio Pacini, M.D., 9 Martin Schlumberger, M.D., 10 Steven I. Sherman, M.D., 11 David L. Steward, M.D., 12 and R. Michael Tuttle, M.D. 13 Background: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the publication of the American Thyroid Association’s guidelines for the man- agement

2009 British Association of Endocrine and Thyroid Surgeons

437. Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review

Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

438. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis

Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

439. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis

Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

440. Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review

Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review Yoo J, Cosby R, Driedger A CRD summary The conclusion that recombinant humanized thyroid (...) -stimulating hormone for radioablation preparation following total or near-total thyroidectomy in patients with papillary or follicular thyroid cancer was equivalent to thyroid hormone withdrawal should be viewed with caution; lack of significant difference is not the same as equivalence in efficacy. Bias was possible and results were based on poorer quality study designs. Authors' objectives To evaluate the therapeutic use of recombinant humanised thyroid-stimulating hormone (rhTSH) for radioiodine

2009 DARE.